Regional Variability in Botulinum Toxin Type A Practices: A Latin American Survey on Dosing, Preferences, and Clinical Outcomes

Dermatological Reviews Pub Date : 2025-10-01 DOI:10.1002/der2.70054

Luis Alberto Parra, Andreina Martinez Amado, Eugenia Cure, Ingrid Salas, Carolina Schneider, Andrea Marcela Parra

{"title":"Regional Variability in Botulinum Toxin Type A Practices: A Latin American Survey on Dosing, Preferences, and Clinical Outcomes","authors":"Luis Alberto Parra, Andreina Martinez Amado, Eugenia Cure, Ingrid Salas, Carolina Schneider, Andrea Marcela Parra","doi":"10.1002/der2.70054","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Regional practices for botulinum toxin type A (BoNT-A) in Latin America remain underexplored. This study characterizes dosing, brand preferences, and clinical outcomes across 12 countries.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To characterize regional variations in BoNT-A dosing, brand preferences, and clinical outcomes for upper facial treatments.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>A cross-sectional survey of 107 practitioners across 12 Latin American countries (March 2025) analyzed dosing (Speywood/International Units), duration, adverse events, and brand preferences using descriptive statistics.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Participants primarily practiced in Colombia (65.4%), Mexico (7.5%), and Central America (4.7%). AbobotulinumtoxinA required higher doses (total upper face: 114.98 ± 24.32 Speywood units) versus IncobotulinumtoxinA (66.36 ± 10.12 IU) and OnabotulinumtoxinA (62.94 ± 7.36 IU). Duration was comparable across brands (12.1–14.3 weeks). Regional preferences included AbobotulinumtoxinA in Brazil (55%) and IncobotulinumtoxinA in Mexico (48%), driven by cost or precision. Adverse events were transient (headache: 58.2%, ptosis: 12.2%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Latin American practitioners balance cost-effectiveness and precision, with standardized dosing reflecting regional expertise. Long-term safety studies are warranted.</p>\n </section>\n </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70054","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatological Reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/ftr/10.1002/der2.70054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Regional practices for botulinum toxin type A (BoNT-A) in Latin America remain underexplored. This study characterizes dosing, brand preferences, and clinical outcomes across 12 countries.

Objective

To characterize regional variations in BoNT-A dosing, brand preferences, and clinical outcomes for upper facial treatments.

Materials and Methods

A cross-sectional survey of 107 practitioners across 12 Latin American countries (March 2025) analyzed dosing (Speywood/International Units), duration, adverse events, and brand preferences using descriptive statistics.

Results

Participants primarily practiced in Colombia (65.4%), Mexico (7.5%), and Central America (4.7%). AbobotulinumtoxinA required higher doses (total upper face: 114.98 ± 24.32 Speywood units) versus IncobotulinumtoxinA (66.36 ± 10.12 IU) and OnabotulinumtoxinA (62.94 ± 7.36 IU). Duration was comparable across brands (12.1–14.3 weeks). Regional preferences included AbobotulinumtoxinA in Brazil (55%) and IncobotulinumtoxinA in Mexico (48%), driven by cost or precision. Adverse events were transient (headache: 58.2%, ptosis: 12.2%).

Conclusion

Latin American practitioners balance cost-effectiveness and precision, with standardized dosing reflecting regional expertise. Long-term safety studies are warranted.

Abstract Image

查看原文本刊更多论文

A型肉毒毒素实践的区域差异：拉丁美洲对剂量、偏好和临床结果的调查

背景：拉丁美洲A型肉毒毒素（BoNT-A）的区域做法仍未得到充分探索。本研究描述了12个国家的剂量、品牌偏好和临床结果。目的探讨BoNT-A给药、品牌偏好和上面部治疗临床结果的区域差异。材料和方法对12个拉丁美洲国家的107名从业人员进行横断面调查（2025年3月），使用描述性统计分析了剂量（Speywood/国际单位）、持续时间、不良事件和品牌偏好。参与者主要在哥伦比亚（65.4%）、墨西哥（7.5%）和中美洲（4.7%）进行练习。与肉毒杆菌毒素ina（66.36±10.12 IU）和肉毒杆菌毒素ina（62.94±7.36 IU）相比，肉毒杆菌毒素ina需要更高的剂量（总上面部：114.98±24.32 Speywood单位）。不同品牌的持续时间具有可比性（12.1-14.3周）。区域偏好包括巴西的肉毒杆菌毒素a（55%）和墨西哥的肉毒杆菌毒素a(48%)，由成本或精度驱动。不良事件为短暂性（头痛：58.2%，上睑下垂：12.2%）。结论拉丁美洲从业人员平衡成本效益和准确性，采用反映区域专长的标准化剂量。长期的安全性研究是有必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatological Reviews

自引率

0.00%

发文量